PANews, October 7: According to official announcements, Injective has released a revised whitepaper—the first comprehensive rewrite since the initial version was published in December 2018. The new version positions Injective as a Layer 1 platform for institutional-grade finance and asset tokenization, covering the full lifecycle of tokenized assets—from issuance and trading to settlement. It introduces native RWA tokenization mechanisms and iAssets derivatives. Tokenized assets can be traded on a fully on-chain central limit order book, with uniform price clearing via sealed high-frequency batch auctions; BFT consensus ensures deterministic finality with block times of approximately 600 milliseconds. The updated whitepaper also covers native EVM and WASM support, perpetual contracts risk management, and AI agent finance, with on-chain protocol revenues directed toward periodic INJ community buybacks.
Injective Releases Updated Whitepaper, Positions Itself as an Institutional-Grade Finance and Asset Tokenization L1
PANewsShare
Summary
Injective has updated its whitepaper, repositioning itself as a Layer 1 blockchain for institutional-grade finance and asset tokenization. The document details native RWA tokenization, iAssets derivatives, and a high-frequency batch auction system. Institutional adoption is a key focus, with features including a 600-millisecond block time, EVM/WASM support, and perpetual risk management. On-chain revenue will fund INJ buybacks, aligning with emerging trends in digital asset news.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.